X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Lead Product(s): Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area: Musculoskeletal Product Name: Trichomylin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg.
Lead Product(s): Cannabichromene
Therapeutic Area: Nutrition and Weight Loss Product Name: Prodiol CBC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: InMed Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
